Core Laboratories Beheer
Beheer criteriumcontroles 3/4
De CEO Core Laboratories is Larry Bruno, benoemd in Feb2018, heeft een ambtstermijn van 8.42 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 4.98M, bestaande uit 17.8% salaris en 82.2% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.56% van de aandelen van het bedrijf, ter waarde $ 2.97M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 6.6 jaar en 5.2 jaar.
Belangrijke informatie
Larry Bruno
Algemeen directeur
US$5.0m
Totale compensatie
| Percentage CEO-salaris | 17.81% |
| Dienstverband CEO | 8.4yrs |
| Eigendom CEO | 0.6% |
| Management gemiddelde ambtstermijn | 6.6yrs |
| Gemiddelde ambtstermijn bestuur | 5.2yrs |
Recente managementupdates
Recent updates
Narratiefupdate • Jun 22
CLB: Refined Assumptions Will Support Undervalued Shares And Future P/E
Analysts have reaffirmed their $22.00 price target on Core Laboratories, citing updated assumptions around the discount rate, revenue growth, profit margin, and forward P/E that refine but do not materially alter their prior valuation view. What’s in the News for Core Laboratories No recent Core Laboratories specific news items were identified in the provided sources.
Narratiefupdate • Jun 07
CLB: Future Middle East Recovery Will Support Reservoir Description Led Upside Potential
Analysts have revised their price target for Core Laboratories to $16.33, with the change supported by updated assumptions around a 7.59% discount rate, 1.85% revenue growth, a 6.35% profit margin, and a future P/E of 24.86x. What's in the News Core Laboratories revised its earnings guidance for the first quarter of 2026, indicating that revenue and earnings are expected to be below the guidance issued on 4 February 2026.Narratiefupdate • May 23
CLB: Middle East Disruptions Will Shape Undervalued Shares And Future P/E
Analysts have kept their $22.00 price target for Core Laboratories unchanged, citing updated assumptions that include a slightly higher discount rate and revenue growth outlook, along with a marginally lower profit margin and P/E expectation. What's in the News Core Laboratories revised its first quarter 2026 guidance, now expecting revenue between US$119,000,000 and US$123,000,000, operating income ex-items of US$5,700,000 to US$7,100,000, and EPS ex-items of US$0.05 to US$0.07, citing impacts from geopolitical conflict in the Middle East, client project delays, travel limits, and supply chain disruptions (Key Developments).Narratiefupdate • Apr 28
CLB: Fair Outlook Balances Middle East Disruptions And Governance Changes
Analysts have raised their price target on Core Laboratories from about $14.00 to roughly $16.33, citing updated views on fair value, discount rate, revenue growth, profit margins, and future P/E assumptions. What's in the News Core Laboratories revised its first quarter 2026 earnings guidance, citing client driven project delays, travel constraints, and supply chain disruptions linked to geopolitical conflict in the Middle East, and now expects revenue of US$119,000,000 to US$123,000,000 and EPS, ex items, of US$0.05 to US$0.07 for the period (Key Developments).Narratiefupdate • Apr 14
CLB: Fair Value View Will Rely On Middle East Risk And P/E Assumptions
Analysts have raised their price target on Core Laboratories from $18 to $22, citing updated assumptions around revenue growth, profit margins, and a slightly higher future P/E multiple as key drivers of the change. What's in the News Core Laboratories revised its first quarter 2026 earnings guidance, citing client driven project delays, travel constraints, and supply chain disruptions linked to geopolitical conflict in the Middle East, and now expects revenue of US$119,000,000 to US$123,000,000, operating income ex items of US$5,700,000 to US$7,100,000, and Earnings Per Share ex items of US$0.05 to US$0.07 (Key Developments).Seeking Alpha • Mar 26
Core Laboratories: Profit Margins Are Too Small To Get Excited About
Summary Core Laboratories remains a HOLD due to persistently low profit margins and unattractive free cash flow yields. Recent Middle East disruptions have significantly impacted CLB’s higher-margin Reservoir Description segment, prompting a downward revision of Q1 EPS guidance. CLB’s capital allocation will continue with a 50/50 split between debt reduction and shareholder returns, targeting leverage below 1.0x. The current valuation at 14x EBITDA is not justified given flat revenues, low margins, and increased operational risks. The stock is valued at low single digit free cash flow yields. Read the full article on Seeking AlphaNarratiefupdate • Jan 26
CLB: Fair Value View Will Rely On Stable Margins And P/E Assumptions
Analysts held their price target on Core Laboratories steady at US$18.00, citing only small tweaks to inputs such as discount rate, revenue growth, profit margin and future P/E assumptions, rather than any major shift in their overall view of the company. Valuation Changes Fair Value: Held steady at US$18.00, indicating no change in the core valuation output.Narratiefupdate • Jan 11
CLB: Fair Value View Will Rely On Stabilizing Margins And EPS
Analysts kept their Core Laboratories fair value estimate around $18.00. The updated price target mainly reflects slightly adjusted assumptions for discount rate, revenue growth, profit margin, and future P/E rather than a major shift in their view of the stock.Narratiefupdate • Dec 14
CLB: Future Earnings And Margins Are Expected To Gradually Stabilize
Analysts have modestly reduced their price target on Core Laboratories by 1 dollar to 18 dollars. This reflects a slightly lower fair value despite improved expectations for revenue growth, profit margin, and a less demanding future price to earnings multiple.Analyse-artikel • Nov 21
A Look At The Fair Value Of Core Laboratories Inc. (NYSE:CLB)
Key Insights Using the 2 Stage Free Cash Flow to Equity, Core Laboratories fair value estimate is US$14.45 Core...Narratiefupdate • Sep 10
Middle East And Asia Pacific Markets Will Secure Energy Success
With both the discount rate and future P/E ratio remaining essentially stable, the consensus analyst price target for Core Laboratories was unchanged at $14.00. What's in the News Core Laboratories issued third quarter 2025 guidance, expecting revenue of $127.5–134.5 million, operating income of $13.6–16.2 million, operating margin of approximately 11%, and EPS of $0.18–0.22.Analyse-artikel • Sep 10
Core Laboratories Inc.'s (NYSE:CLB) 25% Jump Shows Its Popularity With Investors
Core Laboratories Inc. ( NYSE:CLB ) shareholders would be excited to see that the share price has had a great month...Analyse-artikel • Jul 24
We Think Core Laboratories (NYSE:CLB) Is Taking Some Risk With Its Debt
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Analyse-artikel • Jul 03
Core Laboratories (NYSE:CLB) Will Be Hoping To Turn Its Returns On Capital Around
When it comes to investing, there are some useful financial metrics that can warn us when a business is potentially in...Analyse-artikel • Jun 12
Is There An Opportunity With Core Laboratories Inc.'s (NYSE:CLB) 49% Undervaluation?
Key Insights The projected fair value for Core Laboratories is US$23.89 based on 2 Stage Free Cash Flow to Equity Core...Analyse-artikel • Apr 04
Core Laboratories Inc.'s (NYSE:CLB) Price In Tune With Earnings
With a price-to-earnings (or "P/E") ratio of 20x Core Laboratories Inc. ( NYSE:CLB ) may be sending bearish signals at...Analyse-artikel • Jan 21
Is Core Laboratories Inc. (NYSE:CLB) Trading At A 27% Discount?
Key Insights Using the 2 Stage Free Cash Flow to Equity, Core Laboratories fair value estimate is US$27.00 Core...Analyse-artikel • Jan 03
Core Laboratories Inc. (NYSE:CLB) Not Lagging Market On Growth Or Pricing
When close to half the companies in the United States have price-to-earnings ratios (or "P/E's") below 18x, you may...Analyse-artikel • Dec 09
Returns On Capital At Core Laboratories (NYSE:CLB) Paint A Concerning Picture
To avoid investing in a business that's in decline, there's a few financial metrics that can provide early indications...Analyse-artikel • Nov 12
Is Core Laboratories (NYSE:CLB) Using Too Much Debt?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Nieuw narratief • Sep 24
New Product Launches And Deleveraging To Propel Growth Amidst Geopolitical Challenges
Diversification in geographical markets and services strengthens revenue by expanding market presence and targeting regions with growing demand.Analyse-artikel • Sep 19
Is Core Laboratories Inc. (NYSE:CLB) Trading At A 38% Discount?
Key Insights The projected fair value for Core Laboratories is US$29.58 based on 2 Stage Free Cash Flow to Equity...Analyse-artikel • Aug 14
What You Can Learn From Core Laboratories Inc.'s (NYSE:CLB) P/E
When close to half the companies in the United States have price-to-earnings ratios (or "P/E's") below 17x, you may...Analyse-artikel • Jul 15
We Think Core Laboratories (NYSE:CLB) Can Stay On Top Of Its Debt
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Analyse-artikel • Jun 25
These Return Metrics Don't Make Core Laboratories (NYSE:CLB) Look Too Strong
To avoid investing in a business that's in decline, there's a few financial metrics that can provide early indications...Analyse-artikel • May 02
It's Unlikely That Core Laboratories Inc.'s (NYSE:CLB) CEO Will See A Huge Pay Rise This Year
Key Insights Core Laboratories' Annual General Meeting to take place on 8th of May Salary of US$886.9k is part of CEO...Analyse-artikel • Mar 26
Is Core Laboratories Inc. (NYSE:CLB) Trading At A 25% Discount?
Key Insights The projected fair value for Core Laboratories is US$22.93 based on 2 Stage Free Cash Flow to Equity Core...Analyse CEO-vergoeding
| Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
|---|---|---|---|
| Mar 31 2026 | n/a | n/a | US$29m |
| Dec 31 2025 | US$5m | US$887k | US$30m |
| Sep 30 2025 | n/a | n/a | US$32m |
| Jun 30 2025 | n/a | n/a | US$30m |
| Mar 31 2025 | n/a | n/a | US$28m |
| Dec 31 2024 | US$6m | US$887k | US$31m |
| Sep 30 2024 | n/a | n/a | US$26m |
| Jun 30 2024 | n/a | n/a | US$24m |
| Mar 31 2024 | n/a | n/a | US$38m |
| Dec 31 2023 | US$8m | US$887k | US$37m |
| Sep 30 2023 | n/a | n/a | US$41m |
| Jun 30 2023 | n/a | n/a | US$39m |
| Mar 31 2023 | n/a | n/a | US$24m |
| Dec 31 2022 | US$6m | US$820k | US$19m |
| Sep 30 2022 | n/a | n/a | US$15m |
| Jun 30 2022 | n/a | n/a | US$9m |
| Mar 31 2022 | n/a | n/a | US$10m |
| Dec 31 2021 | US$7m | US$820k | US$20m |
| Sep 30 2021 | n/a | n/a | US$31m |
| Jun 30 2021 | n/a | n/a | US$33m |
| Mar 31 2021 | n/a | n/a | US$19m |
| Dec 31 2020 | US$5m | US$820k | -US$97m |
| Sep 30 2020 | n/a | n/a | -US$101m |
| Jun 30 2020 | n/a | n/a | -US$80m |
| Mar 31 2020 | n/a | n/a | -US$55m |
| Dec 31 2019 | US$3m | US$531k | US$94m |
Compensatie versus markt: De totale vergoeding ($USD 4.98M ) Larry } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 2.40M ).
Compensatie versus inkomsten: De vergoeding van Larry is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.
CEO
Larry Bruno (66 yo)
8.4yrs
Tenure
US$4,980,491
Compensatie
Mr. Lawrence V. Bruno, also known as Larry, serves as Chairman of Board and Chief Exertive Officer at Core Core Laboratories Inc. since May 20, 2020. He has been Director of Core Laboratories N.V. since Ma...
Leiderschapsteam
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| Chairman of the Board | 8.4yrs | US$4.98m | 0.56% $ 3.0m | |
| Senior VP & CFO | 8.2yrs | US$1.86m | 0.24% $ 1.3m | |
| Senior Vice President of Corporate Development & Investor Relations | 9.9yrs | US$1.14m | 0.072% $ 383.8k | |
| Senior VP | 5yrs | US$1.15m | 0.063% $ 337.6k | |
| VP, Treasurer & Chief Accounting Officer | 2.3yrs | geen gegevens | 0.019% $ 101.2k | |
| Vice President of People | 2.5yrs | geen gegevens | geen gegevens |
6.6yrs
Gemiddelde duur
56yo
Gemiddelde leeftijd
Ervaren management: Het managementteam van CLB is doorgewinterd en ervaren (gemiddelde ambtstermijn van 6.6 jaar).
Bestuursleden
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| Chairman of the Board | 8.2yrs | US$4.98m | 0.56% $ 3.0m | |
| Independent Director | 3.1yrs | US$201.80k | 0.052% $ 274.9k | |
| Independent Director | 1.2yrs | US$129.41k | 0.018% $ 93.2k | |
| Independent Director | 4.5yrs | US$205.55k | 0.064% $ 338.3k | |
| Independent Director | 6.2yrs | US$215.55k | 0.11% $ 577.8k | |
| Lead Independent Director | 10.5yrs | US$253.05k | 0.12% $ 628.3k | |
| Independent Director | 5.2yrs | US$218.05k | 0.073% $ 388.0k |
5.2yrs
Gemiddelde duur
68yo
Gemiddelde leeftijd
Ervaren bestuur: De raad van bestuur van CLB wordt beschouwd als ervaren (gemiddelde ambtstermijn 5.2 jaar).
Bedrijfsanalyse en status van financiële gegevens
| Gegevens | Laatst bijgewerkt (UTC-tijd) |
|---|---|
| Bedrijfsanalyse | 2026/07/15 00:40 |
| Aandelenkoers aan het einde van de dag | 2026/07/15 00:00 |
| Inkomsten | 2026/03/31 |
| Jaarlijkse inkomsten | 2025/12/31 |
Gegevensbronnen
De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.
| Pakket | Gegevens | Tijdframe | Voorbeeld Amerikaanse bron * |
|---|---|---|---|
| Financiële gegevens bedrijf | 10 jaar |
| |
| Consensus schattingen analisten | +3 jaar |
|
|
| Marktprijzen | 30 jaar |
| |
| Eigendom | 10 jaar |
| |
| Beheer | 10 jaar |
| |
| Belangrijkste ontwikkelingen | 10 jaar |
|
* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.
Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.
Analysemodel en Snowflake
Details van het analysamodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina, we hebben ook handleidingen over hoe u onze rapporten kunt gebruiken en tutorials op YouTube.
Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.
Industrie en sector
Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.
Bronnen van analisten
Core Laboratories Inc. wordt gevolgd door 30 analisten. 2 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.
| Analist | Instelling |
|---|---|
| James West | Barclays |
| Nicholas Green | Bernstein |
| Saurabh Pant | BofA Global Research |